EMA Authorised: Neulasta (pegfilgrastim) — Amgen Europe B.V.

View source ↗

Summary

EMA authorised Neulasta (pegfilgrastim) by Amgen Europe B.V. to reduce the risk of neutropenia, febrile neutropenia, and chemotherapy-induced febrile neutropeni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Chemotherapy-induced Febrile Neutropenia
• Febrile Neutropenia
• Neutropenia

Drugs mentioned

• NEULASTA (pegfilgrastim)

Snippet

Status: Authorised. Therapeutic area: Cancer;Neutropenia;Febrile Neutropenia;Chemotherapy-Induced Febrile Neutropenia. MAH: Amgen Europe B.V.. Decision date: 28/06/2024